Appeal No. 96-2721
Application No. 08/148,764
This is an appeal from the final rejection of claims 2-8,
50-59, 65-69, 75-79, 86, 87, 90-108, 112 and 113, all the
claims remaining in the present application. A copy of
illustrative claim 112 is appended to this decision.
The examiner relies upon the following references as
evidence of obviousness:
Kadin 4,569,942 Feb. 11, 1986
Young et al. (Young) 4,962,117 Oct. 9, 1990
(filed Nov. 2, 1988)
Appellants' claimed invention is directed to 3-
substituted-2-oxindole derivatives of the recited formula.
According to appellants, the claimed compounds find utility in
treating inflammatory conditions, in eliciting an analgesic
response, in treating interleukin-1 mediated disorders and
immune disfunction, in inhibiting prostaglandin H synthase
2
and in inhibiting biosynthesis of interleukin-1 in a mammal.
The appealed claims stand rejected under 35 U.S.C. § 103
as being unpatentable over Kadin, taken alone, or in
combination with Young.
Upon careful consideration of the opposing arguments
presented on appeal, we agree with appellants that the prior
art applied by the examiner fails to establish a prima facie
-2-
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007